Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.
Open accessThe DOI matches its Crossref record.
Abstract
Two patients (brother and sister, 41 and 39 yr of age, respectively) have been shown to have marked elevation of plasma triglycerides and chylomicrons, decreased low density lipoproteins (LDL) and high density lipoproteins (HDL), a type I lipoprotein phenotype, and a deficiency of plasma apolipoprotein C-II (apo C-II). The male patient had a history of recurrent bouts of abdominal pain often accompanied by eruptive xanthomas. The female subject, identified by family screening, was asymptomatic. Hepatosplenomegaly was present in both subjects. Analytical and zonal ultracentrifugation revealed a marked increase in triglyceride-rich lipoproteins including chylomicrons and very low density lipoproteins, a reduction in LDL, and the presence of virtually only the HDL3 subfraction. LDL were heterogeneous with the major subfraction of a higher hydrated density than that observed in plasma lipoproteins of normal subjects. Apo C-II levels, quantitated by radioimmunoassay, were 0.13 mg/dl and 0.12 mg/dl, in the male and female proband, respectively. A variant of apo C-II (apo C-IIPadova) with lower apparent molecular weight and more acidic isoelectric point was identified in both probands by two-dimensional gel electrophoresis. The marked hypertriglyceridemia and elevation of triglyceride-rich lipoproteins were corrected by the infusion of normal plasma or the injection of a biologically active synthesized 44-79 amino acid residue peptide fragment of apo C-II. The reduction in plasma triglycerides after the injection of the synthetic apo C-II peptide persisted for 13-20 d. These results definitively established that the dyslipoproteinemia in this syndrome is due to a deficiency of normal apo C-II. A possible therapeutic role for replacement therapy of apo C-II by synthetic or recombinant apo C-II in those patients with severe hypertriglyceridemia and recurrent pancreatitis may be possible in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease
Long, J. Z., & Cravatt, B. F. (2011) · Chemical Reviews · doi:10.1021/cr200075y · Cited by 425
Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management
Ganda, O. P., Bhatt, D. L., Mason, R. P., Miller, M., & Boden, W. E. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.061 · Cited by 195
“This outcome was accompanied by reductions in the inflammatory biomarkers CRP, lipoprotein-associated phospholipase A2, and apo CIII.”
BackgroundInfluentialHypertriglyceridemia in the genomic era: a new paradigm
Lewis, G. F., Xiao, C., & Hegele, R. A. (2015) · Endocrine Reviews · doi:10.1210/er.2014-1062 · Cited by 152
A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease
Kei, A. A., Filippatos, T. D., Tsimihodimos, V., & Elisaf, M. S. (2012) · Metabolism · doi:10.1016/j.metabol.2011.12.002 · Cited by 136
Le, N. A., Gibson, J. C., & Ginsberg, H. N. (1988) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38512-6 · Cited by 103
Genetic Mutations Affecting Human Lipoproteins, Their Receptors, and Their Enzymes
Zannis, V. I., Kardassis, D., & Zanni, E. E. (1993) · Advances in Human Genetics 21 · doi:10.1007/978-1-4615-3010-7_3 · Cited by 78
Apolipoprotein genetic variation in the assessment of atherosclerosis susceptibility
Hegele, R. A., Breslow, J. L., & Cloninger, C. R. (1987) · Genetic Epidemiology · doi:10.1002/gepi.1370040302 · Cited by 60
Spinal cord of the rat contains more lipoprotein lipase than other brain regions
Bessesen, D., Richards, C., Etienne, J., Goers, J., & Eckel, R. (1993) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40750-3 · Cited by 58
Apolipoprotein profiling as a personalized approach to the diagnosis and treatment of dyslipidaemia
Renee Ruhaak, L., van der Laarse, A., & Cobbaert, C. M. (2019) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563219827620 · Cited by 38
Nakou, E. S., Filippatos, T. D., Agouridis, A. P., Kostara, C., Bairaktari, E. T., & Elisaf, M. S. (2010) · Lipids · doi:10.1007/s11745-010-3409-0 · Cited by 23
Metadata
- Authors
- Baggio, G., Manzato, E., Gabelli, C., Fellin, R., Martini, S., Enzi, G. B., Verlato, F., Baiocchi, M. R., Sprecher, D. L., & Kashyap, M. L.
- Venue
- Journal of Clinical Investigation
- Published
- 1986-02-01
- Volume
- 77
- Issue
- 2
- Pages
- 520-527
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2064323231
- Cited by
- 119
- References
- 0
- FWCI
- 9.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.